

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Outer carton

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprodolor 50 mg/ml solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml contains 50 mg carprofen

3. PACKAGE SIZE

50 ml

4. TARGET SPECIES

Cattle



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use, intravenous use
The stopper should not be punctured more than 20 times.

7. WITHDRAWAL PERIODS

Withdrawal period:
Meat and offal: 21 days
Milk: Zero hours

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use within 28 days.
Once broached, use by...

9. SPECIAL STORAGE PRECAUTIONS

Do not refrigerate or freeze.
Keep the vial in the outer carton in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Le Vet Beheer B.V.

14. MARKETING AUTHORISATION NUMBERS

Vm 41821/3002

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Amber glass vial – 50 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprodolor



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Carprofen 50 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached, use within 28 days.

Once broached, use by...

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Carprodolor 50 mg/ml solution for injection for cattle

2. Composition

Each ml contains:

Active substance:

Carprofen 50 mg

Excipient(s):

Ethanol 96% 0.1 ml

Clear yellowish solution

3. Target species

Cattle.

4. Indications for use

The product is indicated as an adjunct to antimicrobial therapy to reduce clinical signs in acute infectious respiratory disease and acute mastitis in cattle.

5. Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals suffering from cardiac, hepatic or renal impairment.

Do not use in animals suffering from gastro-intestinal ulceration or bleeding.

Do not use where there is evidence of a blood dyscrasia.

6. Special warnings

Special precautions for safe use in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic drugs should be avoided.

Do not exceed the stated dose or the duration of treatment.

Do not administer other NSAID's (non-steroidal anti-inflammatory drugs) concurrently or within 24 hours of each other.

As NSAID therapy can be accompanied by GI or renal impairment, adjunctive fluid therapy should be considered especially in the case of acute mastitis treatment.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Carprofen, in common with other NSAIDs, has been shown to exhibit photosensitising potential in laboratory studies. Avoid contact with skin and eyes. Should this occur, wash the affected areas immediately. Seek medical attention if irritation persists.

Care should be taken to avoid accidental self-injection. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy:

The safety of the veterinary medicinal product has not been established during pregnancy.

Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

No specific significant drug interactions have been reported for carprofen. During clinical studies in cattle four different antibiotic classes were used, macrolides, tetracyclines, cephalosporins and potentiated penicillins without known interactions. However, in common with other NSAIDs, carprofen should not be administered simultaneously with another veterinary medicinal product of the NSAID or glucocorticoid class. Animals should be carefully monitored if carprofen is administered simultaneously with an anticoagulant.

NSAID's are highly bound to plasma proteins and may compete with other highly bound medicines, such that concomitant administration may result in toxic effects.

Overdose:

In clinical studies, no adverse signs were reported after intravenous and subcutaneous administration of up to 5 times the recommended dose.

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAID's, should be applied.

Special restrictions for use and special conditions for use:

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

7. Adverse events

Cattle:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site reaction ^a
--	--------------------------------------

^a transient

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder <or the local representative of the marketing authorisation holder> using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

For subcutaneous or intravenous use.

Single injection of 1.4 mg of carprofen/ kg of body weight (corresponding to 1 ml of the product /35 kg bodyweight) in combination with antibiotic therapy where appropriate.

9. Advice on correct administration

The stopper should not be punctured more than 20 times.

10. Withdrawal periods

Meat and offal: 21 days

Milk: Zero hours

11. Special storage precautions

Keep out of the sight and reach of children.

Do not refrigerate or freeze.

Keep the vial in the outer carton in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after Exp. The expiry date refers to the last day of the month.

Shelf life after first opening the immediate packaging: 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or <household waste>.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

<Ask your <veterinary surgeon> <or> <pharmacist> how to dispose of medicines no longer required.>

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Marketing authorisation numbers: 41821/3002

50 ml amber glass (Type I) vials capped with chlorobutyl rubber stopper retained by an aluminium crimped seal in a cardboard box.

15. Date on which the package leaflet was last revised

September 2023

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder <and contact details to report suspected adverse reactions>:


Le Vet Beheer B.V.
Wilgenweg 7
3421 TV Oudewater
The Netherlands
Tel.: +31 348 563434

Manufacturer responsible for batch release:

Produlab Pharma B.V.
Forellenweg 16
4941 SJ Raamsdonksveer
The Netherlands

<Local representatives and contact details to report suspected adverse reactions:>

17. Other information

A handwritten signature in black ink, consisting of several loops and a final flourish.

Approved: 31 January 2024